Earnings summaries and quarterly performance for Terns Pharmaceuticals.
Executive leadership at Terns Pharmaceuticals.
Board of directors at Terns Pharmaceuticals.
Research analysts covering Terns Pharmaceuticals.
Recent press releases and 8-K filings for TERN.
Terns Pharmaceuticals Highlights Strong TERN-701 Data and Development Path for CML
TERN
Product Launch
New Projects/Investments
- Terns Pharmaceuticals is developing TERN-701 for chronic myeloid leukemia (CML), with data presented in December showing 75% Major Molecular Response (MMR) achievement and over 30% deep molecular response rates at doses of 320mg and above, which is 2-3 times higher than asciminib in a similar patient population.
- TERN-701 demonstrated a clean safety profile with low rates of cytopenias and no signals for hypertension or pancreatic toxicity, and showed efficacy in asciminib-refractory patients.
- Key upcoming milestones include dose selection and an end-of-phase 2 meeting with the FDA mid-2026 to discuss the design of a second-line plus registrational study, which is expected to launch in H2 2026 or early 2027.
- The company is funded through the commercialization and launch of the second-line plus product.
1 day ago
Terns Pharmaceuticals Details Strong TERN-701 CML Data and Future Development
TERN
New Projects/Investments
Product Launch
- Terns Pharmaceuticals' lead candidate, TERN-701, for chronic myeloid leukemia (CML) demonstrated unprecedented data with a 75% Major Molecular Response (MMR) achievement at doses of 320 mg and above, which is 2x-3x higher than asciminib in a similar patient population.
- TERN-701 exhibits a clean safety profile with low cytopenia rates and no hypertension or pancreatic toxicity signals, and crucially, lacks a food effect, addressing significant unmet needs in CML treatment.
- The company plans an end-of-phase II FDA meeting mid-year to discuss the design of its first registrational study for a second-line plus CML population, with study launch anticipated in late 2026 or early 2027.
- Terns Pharmaceuticals is funded through the commercialization and launch of TERN-701 for the second-line plus indication.
1 day ago
Terns Pharmaceuticals Highlights Strong TERN-701 Data and Outlines Development Path for CML
TERN
Product Launch
New Projects/Investments
- Terns Pharmaceuticals' TERN-701 demonstrated 75% Major Molecular Response (MMR) achievement in third-line plus chronic myeloid leukemia (CML) patients at doses of 320 mg and above, showing 2-3 times the efficacy of other agents and a clean safety profile.
- TERN-701 has shown unique efficacy in asciminib-refractory patients and is considered a potential best-in-disease frontline drug for CML due to its superior efficacy, safety, and lack of food effect.
- The company plans an end-of-phase 2 meeting with the FDA mid-2026 to discuss the design of its first registrational study for TERN-701 in a second-line plus CML population, with the study launch expected in late 2026 or early 2027.
- Terns Pharmaceuticals is funded through the commercialization and launch of the second-line plus TERN-701 product.
1 day ago
Terns Pharmaceuticals Discusses CML Focus and TERN-701 Clinical Data
TERN
New Projects/Investments
Guidance Update
- Terns Pharmaceuticals (TERN) has transitioned its focus to chronic myeloid leukemia (CML) with its lead asset, TERN-701, a next-generation allosteric BCR-ABL inhibitor.
- Data presented at ASH in December for TERN-701 showed a 75% Major Molecular Response (MMR) achievement rate by 24 weeks and a 36% Deep Molecular Response rate at go-forward doses, which are 2 to 3 times higher than Scemblix.
- TERN-701 demonstrates a differentiated safety profile, with no observed hypertension or pancreatic toxicity and significantly lower cytopenias compared to Scemblix, which has a 20% rate of these toxicities.
- The company plans an end-of-Phase 2 meeting with the FDA mid-year to finalize the go-forward dose and discuss pivotal study designs for second-line-plus and frontline CML, with a frontline study potentially starting in 2027. The CML market has about 17,000 incident patients annually in the G7.
3 days ago
Terns Pharmaceuticals Discusses TERN-701 Clinical Data and CML Market Strategy
TERN
New Projects/Investments
Product Launch
- Terns Pharmaceuticals (TERN) is advancing TERN-701, a next-generation allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML), having transformed from a metabolic company to focus on CML.
- Clinical data for TERN-701 presented at ASH in December showed a 75% Major Molecular Response (MMR) achievement rate at 6 months in primarily third-line plus CML patients, which is 2-3 times higher than Scemblix, and a differentiated safety profile without hypertension or pancreatic toxicity.
- The company plans an end-of-phase 2 meeting with the FDA mid-year to select the go-forward dose and discuss pivotal study designs, with a frontline study for TERN-701 potentially initiating in 2027.
- The CML market presents a substantial opportunity, with approximately 17,000 incident frontline patients annually in the G7 and a prevalent population of 100,000 patients; a competitor's market guidance was recently revised to $4 billion.
3 days ago
Terns Pharmaceuticals Details CML Market Opportunity and TERN-701 Clinical Progress
TERN
New Projects/Investments
Guidance Update
- Terns Pharmaceuticals has transitioned its focus to Chronic Myeloid Leukemia (CML) with its lead asset, TERN-701, a next-generation allosteric BCR-ABL inhibitor.
- Clinical data for TERN-701 in third-line plus CML patients demonstrated a 75% Major Molecular Response (MMR) achievement rate by 24 weeks and a 36% deep molecular response rate at go-forward doses, which are 2-3 times higher than asciminib.
- TERN-701 exhibits a differentiated safety profile without the hypertension or pancreatic toxicity seen with asciminib, and offers the convenience of no food effect.
- The company plans an end-of-phase II meeting with the FDA mid-year to finalize the dose and design for a pivotal second-line-plus study, with a frontline study potentially initiating in 2027.
- The CML market represents a substantial opportunity, with 17,000 incident frontline patients annually in the G7 and a prevalent population of 100,000 patients; a competitor's market guidance was recently revised to $4 billion.
3 days ago
Terns Pharmaceuticals Discusses Promising TERN-701 Data and Strategic Focus on Oncology
TERN
Product Launch
New Projects/Investments
- Terns Pharmaceuticals presented promising Phase I CARDINAL data for TERN-701 in CML, reporting 75% Major Molecular Response (MMR) and 36% Deep Molecular Response (DMR) in expansion cohorts.
- The company plans to engage with the FDA mid-year 2026 to finalize dose selection and pivotal trial designs for second-line plus and first-line CML, with an aim to directly advance to a second-line plus pivotal study.
- Management expressed strong confidence in TERN-701's efficacy, anticipating it to be meaningfully superior to asciminib with no overlap in confidence intervals for doses of 320mg and above.
- Terns Pharmaceuticals is strategically shifting its focus to oncology, actively seeking to license out its metabolic portfolio (TERN-501, THR-β, and TERN-801).
Mar 2, 2026, 8:50 PM
Terns Pharmaceuticals Discusses TERN-701 Development and Strategic Focus
TERN
New Projects/Investments
Guidance Update
M&A
- Terns Pharmaceuticals' TERN-701 Phase I CARDINAL data, presented at ASH, showed strong efficacy with 75% MMR and 36% DMR in expansion cohorts, and a 62% MR2 among 63 patients. The most common adverse events were hematologic AEs, which were significantly lower than other therapies, and there was no particular signal or high degree of non-hematologic AEs.
- The company plans to meet with the FDA mid-year 2026 to discuss dose selection and pivotal trial designs for second line plus and first line indications, aiming for alignment to move directly into pivotal trials.
- TERN-701 is differentiated from asciminib by its better safety profile, higher target coverage, and lack of food effect, allowing for potentially higher target coverage at higher doses.
- As of early December 2025, 85 patients were enrolled in the CARDINAL study, and Terns expects to release more comprehensive data later in 2026, including more than the 63 patients presented at ASH.
- Terns Pharmaceuticals is focusing on oncology and is actively looking to license out its metabolic portfolio, including TERN-501, THR-β, and TERN-801.
Mar 2, 2026, 8:50 PM
Terns Pharmaceuticals Discusses TERN-701 CML Program and Strategic Focus
TERN
New Projects/Investments
M&A
- Terns Pharmaceuticals provided an update on its TERN-701 program for Chronic Myeloid Leukemia (CML) at the 46th Annual TD Cowen Healthcare Conference, emphasizing its potential for improved safety and efficacy over existing treatments.
- The CARDINAL Phase 1/2 data for TERN-701 demonstrated strong efficacy, with 75% Major Molecular Response (MMR) and 36% Deep Molecular Response (DMR) observed in expansion cohorts.
- The company plans to meet with the FDA mid-2026 to discuss dose selection and pivotal trial designs, aiming to advance TERN-701 into second-line plus and first-line pivotal trials.
- Terns expressed confidence in TERN-701's differentiation, noting no overlap in efficacy confidence intervals when compared to asciminib at the 320mg and 500mg doses.
- Terns is actively seeking to license out its metabolic portfolio, including TERN-501, THR-β, and TERN-801, to concentrate its efforts on oncology.
Mar 2, 2026, 8:50 PM
Terns Pharmaceuticals secures exclusive worldwide license for TERN-701
TERN
New Projects/Investments
Product Launch
- On January 16, 2026, Terns Pharmaceuticals, Inc. entered into an Amendment with Hansoh (Shanghai) Healthtech Co., Ltd., granting Terns an exclusive, worldwide license (excluding the Hansoh Territory) for therapeutic products containing TERN-701.
- This license covers patents invented by Hansoh related to TERN-701, replacing a prior non-exclusive license.
- Terns Pharmaceuticals is obligated to pay Hansoh a one-time upfront license fee of $1.0 million and tiered royalties ranging from 0.75% to 1.25% on annual net sales of TERN-701 products in its licensed territory.
Jan 22, 2026, 9:07 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more